🇺🇸 FDA
Pipeline program

Upadacitinib

M23-699

Phase 3 small_molecule active

Quick answer

Upadacitinib for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie
Indication
Systemic Lupus Erythematosus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials